['seasonal allergic rhinitis']
['molo 1 (also referred as gsp 301-2 ns)', 'molo 2 (also referred as gsp 301-1 ns)', 'placebo nasal spray', 'dymista nasal spray', 'patanase nasal spray']

        Inclusion Criteria:

          -  Male and female patients aged 18 to 65 years (inclusive) with a clinical history of
             seasonal allergic rhinitis (SAR) (for at least 2 years) and exhibiting a positive skin
             prick test

        Exclusion Criteria:

          -  Pregnant or lactating women

          -  Patients with known hypersensitivity to any of the components of the formulation

          -  Patients with a history of seasonal asthma during ragweed season.

          -  Patient requiring chronic use of inhaled or systemic corticosteroids

          -  Patients with perennial rhinitis; non-allergic rhinitis; or ocular infection within 3
             weeks before the screening

          -  Patients with history of acute or significant chronic sinusitis or chronic purulent
             post-nasal drip or Rhinitis Medicamentosa as determined by the Investigator.

          -  Patients with history of narrow-angle glaucoma, increased intraocular pressure,
             posterior subcapsular cataract, urinary retention, uncontrolled hypertension, severe
             Coronary Artery Disease, Ischemic Heart Disease, uncontrolled Diabetes Mellitus,
             Hyperthyroidism, Renal Impairment or Prostatic Hypertrophy, and those receiving MAO
             inhibitor therapy.
      